Last reviewed · How we verify

Gabapentin1200 mg

Zagazig University · FDA-approved active Small molecule Quality 5/100

Gabapentin1200 mg is a Small molecule drug developed by Zagazig University. It is currently FDA-approved. Also known as: gaptin.

Gabapentin 1200 mg, marketed by Zagazig University, is a well-established drug in the pharmaceutical market with a key composition patent expiring in 2028. The drug's primary strength lies in its strong patent protection, which helps maintain market exclusivity and revenue stability. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic nameGabapentin1200 mg
Also known asgaptin
SponsorZagazig University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Gabapentin1200 mg

What is Gabapentin1200 mg?

Gabapentin1200 mg is a Small molecule drug developed by Zagazig University.

Who makes Gabapentin1200 mg?

Gabapentin1200 mg is developed and marketed by Zagazig University (see full Zagazig University pipeline at /company/zagazig-university).

Is Gabapentin1200 mg also known as anything else?

Gabapentin1200 mg is also known as gaptin.

What development phase is Gabapentin1200 mg in?

Gabapentin1200 mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing